New diagnostics and spatial analytics launches rolled out for research and translational programs. Qlucore introduced Qlucore Insights for bladder cancer, a research-use-only whole-transcriptome-based test designed to support tumor staging and grading workflows. ACT Genomics updated ACTDrug, expanding its next-gen sequencing genomic profiling panel to 101 clinically relevant genes with a reported seven working day turnaround. Precede Biosciences launched Precede Bio Insight, a plasma-based epigenomic profiling test for research use that aims to predict therapeutic response and resistance via machine learning. Industry impact: these launches reflect continued commercialization of sequencing, epigenomics, and high-plex spatial proteomics platforms that can be leveraged in trial stratification and biomarker development across oncology cohorts.